Patient characteristics are shown below. A total of 1,607 patients were included in the overall survival analysis and 1,455 patients in the FACT-P analysis.
The median survival of the whole cohort regardless of age was 19.8 months, and the median time to progression of FACT-P score was 10.1 months.
In this cohort, overall survival and time to progression of FACT-P score were lower in patients older than 75. The median overall survival was 19.5 months in patients younger than 75 and 16.6 months in patients older than 75. The median time to FACT-P progression was 11 months in patients younger than 75 and 7.5 months in patients older than 75.
When utilizing a multivariable Cox-regression model including the covariates listed above, the association between age at a cutoff of 75 and overall survival was not statistically significant (HR 1.13, HR = 0.231). However, the association between age greater than 75 and worsening of FACT-P score was significant (HR 1.55, p = 0.0001).
In summary, while numerically lower, overall survival was not significantly different in this retrospective analysis between patients younger or older than 75 receiving docetaxel for mCRPC. Patients older than 75 had a significantly shorter time to worsening in quality of life as assessed by FACT-P score. Optimal treatment regimens that focus both on survival and quality of life in patients, especially those older than 75, are critical to maximizing the quality and quantity of life in patients with mCRPC.
Presented by: Irene Paredero Perez, MD, Medical Oncology Department, Consorcio Hospitalario Provincial de Castellon, Castellon De La Plana, Spain
Written by: Alok Tewari, MD, Ph.D., Medical Oncologist at the Dana-Farber Cancer Institute, at the 2020 European Society for Medical Oncology Virtual Congress (#ESMO20), September 19th-September 21st, 2020